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Abstract 
Purpose: To prepare chondroitin sulphate–polyvinyl alcohol cross-linked microcapsules (miCAPs) for 
controlled delivery of 5-flurouracil (5-FU) in cancer patients.  
Method: Nine different miCAP formulations were prepared using emulsion cross-linking procedure. The 
formulations were evaluated for their physicochemical properties, complex formation, stability at variable 
temperatures, safety, as well as drug-loading and drug-release characteristics. The effects of 
glutaraldehyde (GA), polymer concentration and stirring speed on 5-FU release at various pH were also 
assessed. 
Results: One of the miCAP formulations (miCAP-1) was adjudged the most suitable based on its 
particle size, high drug loading (75.3 %, p = 0.034), and high entrapment efficiency (85.2 %, p = 0.031). 
Best-fit drug release model was Higuchi model based on regression coefficient value (R2) while drug 
release mechanism was Fickian.  
Conclusion: Highly stable, crosslinked, amorphous and drug delivery system has been successfully 
developed. The delivery system is potentially suitable for acid-sensitive therapeutic moieties and where 
controlled release is desired. 
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Microcapsules (miCAPs) refer to tiny, non-toxic 
particles of size below 200 micrometers, which 
are used as high-capacity carriers for several 
drug molecules. They are compatible with 
biological systems, and are characterized by 
their efficient capacities for targeted drug 
delivery, thereby ensuring attainment of desired 
clinical outcomes [1]. 
 
Efforts aimed at development of miCAP-based 
targeted drug delivery have continued to engage 
the attention researchers. These studies usually 
focus more on polymers of natural origin, rather 
than their synthetic counterparts, due to the fact 
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that the former are non-toxic, non-immunogenic, 
bio-compatible, and easily biodegraded by 
human gut microflora [2]. 
 
Colon-based targeted systems have the 
advantage of consistently sustaining high 
therapeutic drug levels while protecting it from 
the low pH of gastro-intestinal tract. Natural 
polymers and polymers of synthetic origin have 
been employed in the design of colon-based 
targeted drug delivery applications. Other types 
of targeted drug delivery systems include 
osmotically-controlled devices, pro-drug systems, 
pH-dependent devices, and systems in which the 
carrier is degraded enzymatically[3,4]. 
 
Chondroitin sulphate, a natural, biocompatible 
and water-soluble polymer which consists of 
repeating units of D-glucuronic acid and N-acetyl 
galactosamine, is biodegradable by gram 
negative anaerobic bacteria in colonic segment 
of the large intestine [5]. It has been utilized in 
fabrication of a number of polymeric systems like 
hydrogels, miCAPs, microgels and nanogels. 
Many researchers have also utilized chondroitin 
sulphate in developing colon-targeted drug 
delivery systems [6]. Hydrolysis of polyvinyl 
acetate yields polyvinyl alcohol (PVA) which 
serves as a potential drug carrier for delayed-
release drug delivery systems [7]. 
 
Intracellular metabolism of 5-FU converts it to its 
active form, fluoro-deoxyuridine which is 
employed in treatment of cancers of the 
pancreas, colon, breast and stomach. Due to its 
short in –vivo half-life (less than 30min) and 
variable bioavailability, 5-FU is clinically 
dispensed in oral dosage formulations [8]. To 
overcome the constraints of short half-life, 5-FU 
should be administered through an efficient, 
effective and sustained site-specific delivery, 
especially for etiologies of colonic origin. Site-
specific delivery is of advantage in promoting 
drug availability where it is required, thereby 
eliminating the need for repeated administration 
of the drug while minimizing unwanted adverse 
effects [7]. Various formulations are used for 
controlled delivery of 5-FU. These include 
miCAPs of chondroitin sulphate/chitosan, and 
microspheres of poly (lactide-co-glycolide), 
sodium alginate and pectin [9,10]. 
 
In the present study, chondroitin sulphate was 
successfully grafted with PVA by using 
glutaraldehyde as a potential cross-linker for site-
specific delivery of 5-FU. This approach reduced 
dosing frequency, side effects and cost of 






The drug, 5-FU was a generous gift from 
Pharmedic Laboratories (Pvt) Ltd (Lahore, 
Pakistan). Chondroitin sulfate-A sodium, PVA, 
sodium metabisulphite, grade-1 GA solution and 
Tween-80 were products of Sigma Aldrich 
(Germany). Food-grade paraffin oil was 
purchased from a local market at Multan, 
Pakistan. Magnesium stearate was product of 
Fluka (Italy). All chemicals and reagents used 
were of analytical grade except paraffin oil. 
 
Preparation of miCAPs 
 
The miCAPs were prepared from PVA and 
chondroitin sulphate using a modified emulsion 
cross-linking method incorporating GA as cross-
linker (Table 1). Glutaraldehyde (GA) was 
selected as cross-linker due to its low price, 
availability and high reactivity, i.e., it readily 
produces aldehyde groups as shown in Table 1.  
The exact quantity of chondroitin sulphate was 
taken and dissolved in distilled water (15mL) 
maintained at 60 °C on a magnetic hot plate 
(Stuart series 600, Germany) at 100 rpm until 
clear solution was formed. Exactly 200 mg of 5-
FU was added to the clear solution of chondroitin 
sulphate. This was labelled solution A. Polyvinyl 
alcohol (PVA) was dispersed, with stirring, in 10 
ml distilled water maintained at 60 °C. Stirring 
was continued for 30 min until a clear solution 
was formed. The PVA solution was labelled 
solution B. Solution A and solution B were mixed 
using a magnetic stirrer at 100 rpm to produce 
the aqueous phase. 
 
The external phase was prepared by stirring a 
mixture of 100 mL paraffin oil, 5 % v/v tween-80 
and 0.3 % w/v magnesium stearate at 600 rpm 
for 15 min. The aqueous phase was then added 
drop-wise, with continuous stirring, from a 
micropipette, over a period of 1 h. Stirring was 
thereafter continued for 30min, resulting in a 
water-in-oil emulsion. Finally, 1.5 ml of 25% GA 
solution containing 100 – 200 μl of concentrated 
sulphuric acid was added drop-wise, with 
continuous stirring for the next 2h, leading to 
acetal ring formation due to interaction of 
aldehyde groups with hydroxyl groups of PVA 
and CS.  The resultant suspension was 
transferred into paraffin oil and retained for 1h. 
The supernatant portion was removed by 
decantation to reveal the formed miCAPs which 
were rinsed many times in acetone to eliminate 
oil traces, and then in sodium metabisulphite for 
complete removal of unreacted GA. The pure 
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miCAPs were vacuum-dried and kept in glass 
vials prior to further investigations [11]. 
 
Determination of 5- FU levels 
 
The levels of 5-FU within each prepared miCAP 
were determined spectrophotometrically at 
266nm, coupled with standard regression as 
outlined previously. Each miCAP formulation was 
stirred for 5min at 200 rpm in 50 mL phosphate 
buffer, pH 7.4 at 60 oC, and thereafter allowed to 
stand for 24h before filtration. After dilution, the 
absorbance of the filtrate was read at 266nm. 
The concentration of 5-FU was then determined 
through a standard regression procedure [12]. 
 


















CP-1 200 0.1 0.1 1.5 
CP-2 200 0.7 0.3 1.5 
CP-3 200 0.8 0.2 1.5 
CP-4 200 1 1 1.5 
CP-5 200 1.4 0.7 1.5 
CP-6 200 1.6 0.8 1.5 
CP-7 200 1.5 1.5 1.5 
CP-8 200 2.1 0.9 1.5 
CP-9 200 2.4 0.6 1.5 
 
Evaluation of drug-loading and encapsulation 
efficiency  
 
Encapsulation efficiency, which is an index of 
percentage of drug loaded, was determined. 
Extraction method was used to calculate 
entrapment efficiency and product yield. 
Prepared microcapsules were poured into 
phosphate buffer (50 ml) to facilitate 5-FU 
release. 5-FU content was determined 
spectrophotometrically at 266 nm. Encapsulation 
efficiency and product yield as previously 
described [13]. 
 
Determination of micromeritic properties 
 
All prepared formulations were subjected to 
micromeritic evaluation. The indices determined 
included bulk density, angle of repose, tapped 
density, Hausner ratio and Carr’s compressibility 
index[19]. 
 
Angle of repose 
 
Angle of repose (Ɵ) was calculated by the funnel 
method as in Eq 1. [14]: 
 
  ……………… (1) 
 
where h = height of cone and r = radius of cone. 





Powder blend was transferred into a measuring 
cylinder and initial volume was noted. After this 
weight of the powder was determined and bulk 
density (ρb) was calculated by using following 
equation [14]: 
 




Measuring cylinder containing powder mixture 
was subjected to tapping for specified number of 
tapings. Tapped volume (Vt) was noted and 
tapped density was calculated using Eq 2 [14]. 
 
  ……………… (2) 
 
Carr’s compressibility index 
 
Compressibility index (I) of the powder blend was 
calculated as in Eq 3 [14]. 
 
 ………………. (3) 
 
Where, Vb and Vt are bulk and tapped volume 
respectively.  Carr’s index value between 13 -19 
% confirms good flow and if it is more than 21 % 




It was computed as the ratio of tapped density to 
bulk density [14]. A value < 1.25 is an indication 
of good flow of powder while > 1.25 indicates 
poor flow. 
 
Fourier transform infrared spectroscopy 
(FTIR) 
 
Drug-polymer interaction was investigated by 
ATR-Fourier transform infrared spectroscopy 
(Tensor 27). The IR spectra were obtained for 5-
FU, chondroitin sulphate and PVA; and for 
physical mixtures of drug and polymers, 
unloaded chondroitin sulphate-grafted PVA 
miCAPs, and the 5-FUmiCAPs using ATR-FTIR 
(Tensor 27). The range of wavelengths used for 
the scan was 500 − 4000 cm−1 at a resolution of 
4 cm−1 [15]. 
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GC-MS analysis  
 
Gas chromatographic system (Chemitto 
GC8610) consisting of 30m capillary helium gas 
column (db-5) with long narrow bore, was used 
to estimate GA residues in the miCAPs. The flow 
rate of the gas was kept at 1ml/min, and the 
sample size injected was 1 μl. Pure GA solution 
(1 μl) was injected into the column, and the 
chromatogram was recorded.  
 
Each MiCAP (1g) was accurately weighed, 
poured in 25ml of water and shaken 
mechanically for 24h in a screw capped vial on 
thermos-shaker incubator about 37°C. The 
supernatant was collected using insulin syringe 
after centrifugation at 6000rpm for 10min and it 
was filtered through 0.45 µm syringe filter 
(Sartorius). After appropriate dilution, each 
sample was injected into chromatographic 
system for estimation of GA content [16]. 
 
Thermal characterization of miCAPs and raw 
materials 
 
Chondroitin sulphate, 5-FU, polymer-drug 
mixtures, unloaded miCAPs and PVA were 
analyzed for their phase transition characteristics 
using TA device.  Prior to sample application, the 
pans were subjected to tarring. With the 
reference pan empty, the sample pan was half-
filled, and heat was applied to the furnace, 
raising the temperature to 450 °C at a flow rate 
of 15°C/min in a nitrogen medium [15]. The 
temperature at which melting of the raw materials 
and miCAPs occurred as well as the temperature 
for entire combustion was calculated to assess 
the stability of the miCAPs. 
 
Assessment of effect of miCAP on 
crystallinity of 5-FU and raw materials 
 
Powder x-ray diffraction XRD was employed to 
assess the effect of miCAP formation on 5-FU 
crystallinity, using X-ray diffractor (model; JDX 
3532, JEOL, Japan). The powder x-ray diffraction 
patterns of raw materials and triturated miCAPs 
were obtained at 60 kV and 50 mA using CuKα 
radiation, with a scanning rate of 1°/min over a 
diffraction angle (2q) range of 10° to 40° [17]. 
 
Confirmation of elemental composition of 
miCAPs 
 
The elementatal composition of the miCAPs was 
confirmed using energy dispersive spectroscopy 
(Inca 200, Oxford UK). This technique also 
serves to confirm sucessfull loading of active 
moeity within the carrier system [15]. 
 
Scanning electron microscopy (SEM) 
 
The surface and internal morphologies of the 
miCAP formulations were determined by electron 
microscope scans. For external morphology, the 
scanning electron microscope (SEM) image of 
each powdered miCAP was captured in vacuum 
at 20kV after fixing it to a support and coating it 
with gold by means of a SPI sputter module.  
 
In the assessment of internal morphology, the 
miCAPs were embedded in acrylate glue, dried 
and cut into slices which were placed on 
scanning stubs to obtain the internal SEM 
images [15]. 
 
Determination of particle sizes of miCAPs 
 
Particle size analyzer (Zeta-sizer Nano-series 
ZEN3600, Malvern Instruments Ltd. with 
software DTS-nano, Kingdom) was used for the 
estimation of the particle sizes of the miCAPs 
[15]. 
 
Assessment of drug release in vitro 
 
Drug release from the miCAPs was investigated 
by applying the paddle procedure which involves 
USP dissolution apparatus-II. Accurately 
weighed miCAPs (equivalent to 50 mg of 5-FU) 
was placed in a dialysis bag. The bag was 
attached to a paddle via a thread, and the 
ensemble was placed separately in 900mL of 
three media of different pH: HCl (pH 1.2), 
phosphate buffer (pH 6.8) and phosphate buffer 
(pH 7.4), each for 12h at a rotation speed of 
100rpm.  
 
Triplicate portions (3 mL each) of the medium (3 
mL) were removed at specific time intervals and 
analyzed for drug levels by UV 
spectrophotometry at 266 nm after prior filtration 
using a micro-pore membrane. Each time a 
sample was taken, it was replaced with an equal 
volume of medium. 
 
Release kinetic studies 
 
In order to ascertain the underlying mechanism 
that governed the release of 5-FU from the 
miCAPS, different kinetic models were used to 
analyze the results from assessment of in-vitro 
drug release. The models tested zero order, first 
order, Higuchi and Korsmeyer-Peppas. 
Regression coefficient (r2) values were 
calculated using DD solver Microsoft Excel adds 
in program, V 11.83, UK was utilized and 
regression coefficient (r2) values were calculated 
[18]. 
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Data are expressed as mean ± SD. Statistical 
analysis was carried out using SPSS 18®.  
Comparison among formulations was made by 
applying one–way analysis of variance (ANOVA). 







Values of encapsulation efficiency and drug 
loading were highest in miCAP-1 which 
contained 1% polymer and equal amounts of 
PVA and chondroitin sulphate, and decreased 
with increases in polymer level. When the 
polymer level was 1%, the diameter of the inner 
cavities of the miCAPs was 100 µm, and the 
cavity linings were porous. However, when the 
level of polymer was raised to 2 - 3 %, the 
resultant miCAPs had significantly (p = 0.037) 





The bulk and tapped densities of all miCAPs 
were computed and applied in the determination 
of Hausner ratio and Carr’s index. The results 
obtained revealed that the compactness of the 
miCAPs was directly proportional to polymer 
content in all the formulations. The values of bulk 
density, tapped density, angle of repose, Carr’s 
index and Hausner’s ratio were in the ranges of 
0.2– 0.3 g/ml, 0.3– 0.3 g/ml, 23.21 to 28.21°, 
10.2 - 30.7% and 1.11 – 1.44, respectively. 
These results indicate that the miCAPs had good 
flow properties. 
 
Effect of miCAP formation on the Fourier 
infrared spectra of 5-FU  
 
The formation of miCAPs did not bring about any 
alterations in the Fourier infrared spectrum of 5-
FU, which indicates absence of chemical 
reaction between the drug and the polymeric 
component (Figure1). Glutaraldehyde (GA) 
exposure leads to contact dermatitis, bronchial 
asthma, and eye irritation [24]. The 
chromatograms of pure GA and the prepared 
miCAPs were recorded and compared, to ensure 
absence of unreacted GA. Sharp intense peaks 
were present at different retention times while 
these peaks were completely absent in 
chromatogram of the miCAP formulations, 
indicating the absence of unreacted GA. This is 
in agreement with results obtained in previous 
studies in which the absence of unreacted GA 
was confirmed by gas chromatography [21,25]. 
 
 
Figure 1: FTIR spectra (A) 5-FU (B) chondroitin 




Figure 2: GC-MS chromatograms of glutaraldehyde 
and 5-FU formulation 
 
Thermograms of 5-FU, chondroitin sulphate 
and 5-FU-loaded miCAPs 
 
The thermogram of 5-FU showed a sharp 
endothermic peak at 281 °C which reflected its 
melting point, while another peak was seen at 
200 °C which corresponded to the melting 
temperature of PVA. A broad peak was seen at 
123.8 °C for chondroitin sulphate as a result of 
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its amorphous characteristics (Figure 3a and 
Figure 4a). Furthermore, drug-loaded miCAPs 
did not exhibit the characteristic peak of 5-FU, 
thereby indicating successful entrapment of the 
drug within the miCAPs. Absence of 
characteristic drug peaks after loading has also 




Figure 3: DSC thermograms of (A) unloaded 
microcapsules (B) physical mixture (C) Chondroitin 




Figure 4: TGA curves of (A) 5-FU (B) physical mixture 
(C) 5-FU loaded microcapsules (D) Unloaded 
microcapsules (E) PVA(F) Chondroitin sulphate 
 
PXRD patterns of 5-FU, PVA, chondroitin 
sulphate and 5-FU-loaded miCAPs  
 
The PXRD patterns of 5-FU, PVA, chondroitin 
sulphate, PVA, physical mixture, unloaded 
miCAPs and 5-FU-loaded miCAPs are shown in 
Figure 5. Sharp and intense peaks were 
produced by 5-FU at 2θ ranging from 15.9° to 
32.1°, which revealed that its structure was 
crystalline. This was in contrast to the broad 
peak exhibited by the unloaded miCAPs at 2θ 
ranging from 10° to 25°, which revealed that the 
PVA complex was less crystalline in nature. 
 
 
Figure 5: XRD diffractograms (A) 5-FU (B) chondroitin 
sulphate (C) PVA (D) unloaded microcapsules (E) 5-




EDX spectra showing the elements present in 5-
FU, unloaded and 5-FU-loaded miCAPs are 
presented in Figure 6. The carbon contents of 5-
FU, unloaded miCAPs and loaded miCAPs were 
73.29, 62.49 and 68.21, respectively, while their 




Figure 6: Elemental -ray profile of (A) 5-FU (B) 
unloaded  microcapsules (C) 5-FU loaded miCAPs 
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Morphology of loaded and unloaded miCAPs 
 
The unloaded miCAPs had smooth surfaces and 
spherical morphologies; while the 5-FU-loaded 
miCAPs had slightly rough surfaces (Figure 7).A 
rough surface facilitates penetration of solvent 
and drug diffusion from miCAPs [15,20]. It was 
evident that miCAPs containing 1 % polymer 
(Figure 7, P1) were more spherical in shape, and 
exhibited much smoother surfaces and more 
spherical shapes than those containing 2 – 3 % 
polymer components (Figure 7, P2 and P3). 
 
Spherical, smooth, non-porous surface and 
rough miCAPs were obtained due to effects of  
polymer concentration, stirring speed, stirring 
time and GA concentration. Microcapsules with 
1% polymer load exhibited thin-walled, smooth 
surfaces and larger inner cavity cross sections 
(Figure 7, P1 and C1). On the other hand, 
miCAPs with 2 and 3 % polymeric loads had 
thick-walled, rigid cracked surfaces, and reduced 
inner cavities due to coagulation of polymer and 
rapid solidification. Stirring speeds below 500rpm 
produced agglomerates (Figure 7, S1) having 
irregular morphologies, while stirring 
speedshigher than 600 rpm produced rigid 
miCAPs with compact surfaces (Figure 7, S2). 
Smooth-surface, spherical and regular miCAPs 
were generated at stirring speed of 600 rpm 
(Figure 7, S3). 
 
 
Figure 7: SEM micrographs (P1, P2, P3) 
Microcapsules having 1, 2 and 3 % polymer load: (C1, 
C2, C3).Different cavity size with respect to polymer 
load: (S1, S2, S3); microcapsules prepared at 500 and 
600rpm, and spherical particles: (T1, T2) Thickness of 
microcapsules 
Increases in polymer concentrations resulted in 
higher sizes of particles (Table 2). 
 
Table 2: Particle size, drug loading and entrapment 













































Drug release from miCAP formulations  
 
The amount of 5-FU released from all 
formulations was below 20 % at pH 1.2, but at 
pH 7, the release of 5-FU reached a maximum 
level of 82 % (Figure 8). 
 
 
Figure 8: Release profiles of 5-FU from CP-1 at 
different pH 
 
When the drug release data were subjected to 
kinetic analysis, it was found that in zero order 
kinetics, drug release rate was constant and was 
not a function of drug concentration. On the other 
hand, drug release rate in first order varied with 
the concentration of 5-FU, while in the Higuchi 
model, it varied with . Korsmeyer-Peppas 
is used to determine the mechanism involved in 
the release of drugs from systems. The most 
suitable model was selected on the basis of best 
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fit of data. Values of regression coefficient (r2) 
and release constant (k) were determined for the 
various models. It was revealed that drug release 
from PVA/chondroitin sulphate miCAPs was 
consistent with the Higuchi model, as was 
evident in the relatively high r2 value (Table 3). 
This shows that the release of drug from these 
miCAPs was diffusion-dependent. This 
conclusion was confirmed from the ‘n’ value 
range of 0.27 – 0.5 obtained from Korsmeyer–
Peppas equation by fitting data from 90% drug 
release. 
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Decreases in entrapment efficiency and drug 
loading have been attributed to increases in 
thickness of wall material and reduction of the 
diameter of inner miCAP cavity. In the present 
study, there were reductions in inner cavity 
diameter with increasing polymer load. This is in 
agreement with the findings of Huang et al, who 
demonstrated that 5-FU release in miCAPs 
formulated from chondroitin sulphate and 
chitosan was decreased by increasing polymer 
concentration [21]. 
 
Flow properties are important markers for 
granules, and they influence the flowability and 
compactness of powders. All the formulations 
had excellent flowability. Differential Scanning 
Calorimetery and Thermal Gravimetric analysis 
are very useful tools in the investigation of the 
thermal properties of miCAPs, and they provide 
useful information regarding drug-polymer 
interaction. The presence of an identical 
thermogram for 5-FU in the physical mixture is 
proof that there was no reaction between 5-FU 
and the polymer. The cross-linked polymeric 
complexes (miCAPs) exhibited increased thermal 
stability as demonstrated by decomposition 
temperature which was higher than 300 °C. 
 
The nature of 5-FU miCAPs (crystalline or 
amorphous) was confirmed from PXRD studies. 
The PXRD pattern of the 5-FU loaded miCAPs 
did not show any characteristic peak, which is 
proof of a change from crystalline nature to 
amorphous nature post-encapsulation. The 
absence of the characteristic drug peaks after 
loading into miCAPs has also been reported in 
previous studies [27,28]. The carbon and oxygen 
contents of the 5-FU-loaded miCAPs were 
increased due to successful drug entrapment. 
Similar reductions in carbon and oxygen levels 
have been reported by Rodzinski et al [22]. 
 
Increases in polymer levels resulted in higher 
medium and increased particle size at constant 
stirring speed: smaller fine droplets were not 
produced even at increased polymer load due to 
high viscosity of medium. Similarly, Motlekar et al 
observed increases in miCAP particle sizes, 
which were attributed to accentuated viscosity 
[23].  
The lower release of 5-FU at pH 1.2 could be 
explained by the fact that at acidic pH, cross-
linking hinders free access of water to the 
polymeric network, resulting in reduced water 
diffusion within the miCAP, and hence low 
polymer chain mobility. Drug release was 
maximal at pH 7.4 due to the fact that the acetal 
linkage of GA undergoes hydrolysis at alkaline 
pH, so that 5-FU diffuses more readily and the 
dissolution media penetrates more freely. This 
finding is in agreement with reports in previous 
studies [25]. The results from kinetic modeling of 
drug release studies are consistent with those 




Thermally-stable 5-FU-loadedmiCAPs have been 
successfully prepared by a slightly-modified 
chemical emulsion cross-linking method. This 
approach may also be feasible for formulation of 
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